Related Experiment Video
Updated: Apr 17, 2026

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
Published on: May 26, 2023
The topical corticosteroid classification called into question: towards a new approach.
Philippe Humbert1, Alexandre Guichard
1Research and Studies Center on the Integument (CERT), Department of Dermatology, Clinical Investigation Center (CIC INSERM 1431), Besançon University Hospital, Besançon, France; INSERM UMR1098, FED4234 IBCT, University of Franche-Comté, Besançon, France.
The 1962 vasoconstrictor assay for topical corticosteroids is outdated. Potency does not always correlate with anti-inflammatory effects, necessitating a new classification system for better therapeutic targeting and reduced side effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- The vasoconstrictor assay, established in 1962, was an early method to assess topical corticosteroid potency.
- This assay measures vasoconstriction, a surrogate marker for corticosteroid penetration and local effect.
Discussion:
- Modern understanding reveals that strong vasoconstrictor effects do not consistently predict strong anti-inflammatory activity.
- The evolving knowledge in corticosteroid pharmacology necessitates a re-evaluation of existing classification systems.
- Over-reliance on the vasoconstrictor assay may lead to suboptimal therapeutic choices and patient dissatisfaction.
Key Insights:
- The vasoconstrictor assay is an insufficient measure of topical corticosteroid efficacy.
- A disconnect exists between vasoconstrictive potency and actual anti-inflammatory therapeutic outcomes.
- A new classification system is required to align corticosteroid potency with specific therapeutic targets.
Outlook:
- Developing a novel classification system based on anti-inflammatory efficacy and therapeutic application is crucial.
- This revised classification aims to optimize treatment selection for various dermatological conditions.
- The goal is to enhance therapeutic efficiency, minimize adverse effects, and combat corticophobia.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drug Classes and Categories
Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...

